Congress quietly exempts premium cigars from FDA health oversight

What it does

This bill exempts 'traditional large and premium cigars'—defined as hand-rolled or semi-hand-rolled cigars made entirely from leaf tobacco, weighing at least 6 pounds per 1,000 count—from FDA regulation under the Federal Food, Drug, and Cosmetic Act. The exemption removes FDA authority to regulate these cigars' manufacturing, marketing, or composition, while keeping other tobacco products (cigarettes, little cigars) under FDA oversight.

Why we flagged it

The bill's core function is to exempt a specific tobacco product category from federal health and safety regulation. Despite the title's emphasis on 'small business' and 'jobs,' the mechanism is a narrow regulatory exemption that benefits cigar manufacturers and importers while reducing public-health oversight.

What the text implies

• FDA loses ability to monitor or regulate marketing claims, ingredient disclosures, or health warnings for exempted cigars, creating a regulatory blind spot for a nicotine product.
• The definition's specificity (6 lbs per 1,000 count, hand-rolled or semi-hand-rolled) may be narrowly tailored to protect a particular manufacturer or import category, though the text does not name beneficiaries.
• Exemption from section 907 (which typically covers user fees and compliance reporting) reduces FDA's ability to track production, sales, and market trends for these products.
• The bill does not address marketing to youth or flavoring restrictions, which remain unregulated for exempted cigars under this language.
• Conforming amendments to section 919 remove exempted cigars from user-fee calculations, reducing FDA's funding for tobacco oversight across all products.

Who it affects

Ordinary citizens lose FDA oversight of a tobacco product category, reducing public-health protections and transparency. The exemption benefits cigar manufacturers and importers at the expense of consumer protection, public-health monitoring, and regulatory consistency. Smokers of these products lose access to FDA-mandated disclosures and safety standards.

Who stands to gain

• premium cigar manufacturers
• cigar importers
• hand-rolled cigar producers
• tobacco leaf suppliers (for premium cigar segment)

Named in the bill

FDA, Federal Food, Drug, and Cosmetic Act, Section 901, Section 907, Section 919, Section 900, premium cigar industry, tobacco manufacturers

Where it stands

1 cosponsor: 1 Republicans.

• Feb 25, 2026 — Introduced · Congress.gov: “Introduced in Senate”
• Feb 25, 2026 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $0 in lobbying spend. A filing names 11 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Ashley Moody, the sponsor, reported $2,315,100 in PAC receipts in the 2026 cycle.

• Americans for Nonsmokers' Rights — $0 on 1 filing

Lobbying Disclosure Act filings through Jul 21, 2026. A filing shows who paid to lobby on a bill it names, not what changed.